Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukemia.
B-cell disorders include a large group of malignant and nonmalignant diseases with tremendous variation in incidence, natural history, treatment, and prognosis. This article will focus on adult idiopathic thrombocytopenic purpura (ITP) and chronic lymphocytic leukemia (CLL). Clinicians must individualize treatment for ITP and CLL to each patient. Observation without...

Sterling Biotech to invest Rs 600 cr for expansion.
VADODARA: Sandesara group's Sterling Biotech plans to invest about Rs 600 crore to ramp up the manufacturing capacities of gelatin and coenzyme (Q10) at its facilities in Vadodara. The company is also considering increasing the manufacturing capacity of its recently acquired unit in China. A Sterling Biotech...

ZLB Behring Foundation Calls for Grant Applications.
KING OF PRUSSIA, Pa., Nov. 16 /PRNewswire/ -- The ZLB Behring Foundation for Research and Advancement of Patient Health today announced that it is now accepting grant applications for programs designed to benefit the bleeding disorders community in the United States. At regular intervals throughout the year, the Foundation...

U.S. Court of Appeals To Hear Microbix Argument In May On Trial For Damages.
Annual meeting hears second quarter sales higher TORONTO, March 27 /PRNewswire/ - Microbix Biosystems Inc. (TSE:MBX) today announced a hearing has been scheduled for May 7 by the U.S. Court Of Appeals For The Fourth Circuit to hear oral arguments against Abbott Laboratories and BioWhittaker,...

ViaCell Acquires Cerebrotec to Form Neuroscience Division.
Noted Neuroscientist, Dr. Seth Finklestein, to Head New Division Focusing on Cellular and Molecular Medicines for The Treatment of Stroke and Other Neurological Diseases BOSTON, July 25 /PRNewswire/ -- ViaCell, Inc., a premier cellular pharmaceuticals company, today announced it has acquired...

Orally Administered Panzem Demonstrates Safety in Patients with Breast Cancer; Profile Shows Promise as Candidate for Breast Cancer.
SAN FRANCISCO, and ROCKVILLE, Md., May 13 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced, at the American Society of Oncology (ASCO) Annual Meeting, the successful completion of the first clinical trial of Panzem(TM)(2-Methoxyestradiol) as a single agent in patients with advanced stages of breast cancer. Panzem,...

EntreMed and the National Eye Institute Team Up To Fight Macular Degeneration by Blocking Angiogenesis.
Collaboration Suggests the Potential Application Of Antiangiogenesis Therapy in Treating Blindness ROCKVILLE, Md., June 25 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced a two year Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) to study the role that...

Entremed And Aventis to Collaborate in a Phase II Clinical Trial for Prostate Cancer.
Orally-Active Angiogenesis Inhibitor Panzem(TM) (2me2) to Be Studied in Combination With Taxotere(R) (Docetaxel) ROCKVILLE, Md., June 25 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced a collaborative relationship with Aventis Pharmaceuticals for Phase II clinical studies in patients with hormone refractory prostate cancer....

The body bazaar.
Blood, kidneys, eggs, sperm--name a body part, there's a price on it. Think of it as a commodities market for the twenty-first century. There's a bank in central Boston that offers its customers a unique investment opportunity. For an initial outlay of $2,500 and yearly fees of $95, investors...

MEDICAL MAILBOX.
"Coincidence is God's way of performing a miracle anonymously."--Anonymous Celiac Sprue Dear Dr. SerVaas: For five months, I had increasingly severe diarrhea, some nausea, much gas, and some abdominal discomfort. A barium enema, upper GI, flexible sigmoidoscopy, and many stool specimens were all...